Kiora Pharmaceuticals Inc (KPRX) — Cash Flow-to-Debt Ratio
Kiora Pharmaceuticals Inc (KPRX) has a Cash Flow-to-Debt Ratio of -0.43x as of March 2026, meaning its operating cash flow of $-3.16 Million could theoretically repay 0% of its total liabilities ($7.29 Million) in one year. See KPRX free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kiora Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Kiora Pharmaceuticals Inc across 14 annual periods. Also explore KPRX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Kiora Pharmaceuticals Inc (2012–2025)
Year-by-year debt coverage analysis for Kiora Pharmaceuticals Inc. For market capitalisation and broader financial context, see KPRX stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.23x | $-9.96 Million | $8.13 Million | ▼ -253.6% |
| 2024 | 0.80x | $8.56 Million | $10.72 Million | ▲ +163.5% |
| 2023 | -1.26x | $-9.56 Million | $7.60 Million | ▲ +12.4% |
| 2022 | -1.43x | $-10.43 Million | $7.27 Million | ▲ +25.4% |
| 2021 | -1.92x | $-10.68 Million | $5.55 Million | ▼ -46.5% |
| 2020 | -1.31x | $-7.32 Million | $5.57 Million | ▲ +43.8% |
| 2019 | -2.34x | $-8.15 Million | $3.49 Million | ▼ -15.1% |
| 2018 | -2.03x | $-10.84 Million | $5.34 Million | ▼ -409.2% |
| 2017 | -0.40x | $-6.47 Million | $16.23 Million | ▲ +52.3% |
| 2016 | -0.84x | $-8.41 Million | $10.06 Million | ▲ +35.8% |
| 2015 | -1.30x | $-4.46 Million | $3.42 Million | ▼ -5581.3% |
| 2014 | -0.02x | $-950.62K | $41.43 Million | ▲ +69.8% |
| 2013 | -0.08x | $-2.96 Million | $38.98 Million | ▲ +46.0% |
| 2012 | -0.14x | $-5.22 Million | $37.16 Million | — |